Bioventus (BVS) EBITDA (2020 - 2026)

Bioventus has reported EBITDA for 7 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 263.59% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $34.3 million (up 190.75% YoY), and the FY2025 full-year result was $28.1 million, up 154.87% from the prior year.
• EBITDA for Q1 2026 stood at $3.5 million, down from $17.2 million in the prior quarter.
• The five-year high for EBITDA was $17.2 million in Q4 2025, with the low at -$138.6 million in Q2 2023.
• Historically, EBITDA has averaged -$19.0 million across 5 years, with a median of -$7.0 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA plunged 3761.78% — and 2025, when it jumped 496.53%.
• Bioventus' EBITDA stood at -$33.9 million in 2022, then surged by 78.88% to -$7.2 million in 2023, then soared by 39.27% to -$4.3 million in 2024, then jumped by 496.53% to $17.2 million in 2025, then slumped by 79.83% to $3.5 million in 2026.
• The last three EBITDA figures came in at $3.5 million (Q1 2026), $17.2 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.